This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Alpelisib Plus Olaparib in Platinum-resistant/Refr...
Clinical trial

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Read time: 1 mins
Last updated:27th Jan 2021
Status: Not yet recruiting
Identifier: NCT04729387
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest